Seer (SEER) Proxy filing summary

Executive summary

• Annual Meeting scheduled for July 28, 2026, with voting eligibility for shareholders of record as of May 29, 2026.

• Board urges shareholders to vote for all seven incumbent director nominees using the BLUE proxy card.

• Board highlights the company's leadership in proteomics and the strategic importance of current directors.

• Forward-looking statements address ongoing strategies, R&D initiatives, and business objectives.

Voting matters and shareholder proposals

• Shareholders are asked to elect seven directors at the Annual Meeting.

• Competing slate proposed by Bradley Radoff and Michael Torok seeks to replace three incumbent directors.

• Board opposes the alternative nominees, citing lack of relevant experience and alignment.

Board of directors and corporate governance

• Current board includes experienced leaders in proteomics, healthcare investing, and technology growth.

• Incumbent nominees: Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Dipchand Nishar, Isaac Ro, and Nicolas Roelofs.

• Board emphasizes the importance of relevant industry expertise and long-term alignment with shareholders.

• Board unanimously determined that dissident nominees lack necessary skills and independence.